Reviewer No. 2 checklist for: DMARDS Review for children. In the WHO Essential Medicines List
|
|
- Beverly Hopkins
- 5 years ago
- Views:
Transcription
1 Reviewer No. 2 checklist for: DMARDS Review for children In the WHO Essential Medicines List (1) Have all important studies that you are aware of been included? (2) Is there adequate evidence of efficacy for the proposed use? Yes No X (3) Is there evidence of efficacy in diverse settings and/or populations? Yes No X (4) Are there adverse effects of concern? (5) Are there special requirements or training needed for safe/effective use? (6) Is this product needed to meet the majority health needs of the population? Yes No X (7) Is the proposed dosage form registered by a stringent regulatory authority? (8) What action do you propose for the Committee to take? According to the previous review, I propose the inclusion of methotrexate and hydroxychloroquine, taking into account the available evidence for rheumatic diseases in children and the more favourable side effects profile of these medicines. (9) Additional comment, if any. Summarizing Dr. Peter Gowdie s comprehensive review and adding some comments to justify or not the inclusion of DMARDs for children in the WHO Model List of Essential Medicines, taking into account the criteria based on evidence and the character of essentiality. The most known chronic inflammatory disorders in a paediatric setting involving the joints and connective tissues are juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), and systemic lupus erythematosus (SLE). They can present systemic clinical involvement and complications. Characteristically, these diseases present flares and a chronic relapsing and remitting course. The systemically affected patients might have worse prognosis and outcomes, with disability and increased risk of complications. All of these conditions are uncommon or rare diseases affecting children worldwide. Their
2 reported prevalence is variable, and mostly described in Caucasian population. Non Caucasian ethnicity is associated with increased paediatric SLE disease prevalence. Non Caucasian SLE patients were significantly younger and more likely to have nephritis. However, disease activity and damage were strongly associated with major organ disease independent of the patientʹs ethnicity Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 2009; 36(11): The management of these diseases is often evaluated by non controlled studies, with small sample size, selection bias, powerless design and no relevant clinical outcomes. Therefore the evidence of efficacy is poor. In consequence, it is difficult to estimate the global burden of these diseases and the impact of their pharmacological treatment. As inflammatory and autoimmune diseases, their treatment includes the following pharmacological classes: 1. Non Steroidal Antiinflammatory Medicines (NSAIMS) frequently used for symptomatic management of musculoskeletal complaints (pain, discomfort and morning stiffness). 2. Corticosteroids in immunosuppressive doses and added to supportive care remain the first line therapies for the management of paediatric SLE and are the mainstays of treatment of JDM. 3. Disease Modifying Agents in Rheumatoid Disorders (DMARDs) including immunosuppressive agents (methotrexate, cyclophosphamide, azathioprine, cyclosporinee, mycophenolate, leflunomide), a sulfonamide agent (sulfasalazine), and antimalarial agents (chloroquine or hydroxychloroquine). The immunosuppressive agents have not been subjected to randomised controlled trials. However they are accepted in the management of these diseases for their long term beneficial effects in controlling disease activity. In general, they work reinforcing corticosteroid effects or reducing their dosage and the longterm exposure to them. They are generally considered early in the course of the disease if there is evidence of systemic involvement and target organ damage. They are also warrantable in patients resistant to corticotherapy, or facing unbearable associated corticoid toxic effects, or with a relapsing course of disease, or at risk of developing irreversible organ damage. Introductory comments: 1 In this issue, the considered inflammatory and autoimmune diseases are rare or uncommon in children worldwide. As a matter of fact, this call in question the character of essentiality of medicines to be included ( Essential medicines are those that satisfy priority health care needs. ). However, these chronic diseases might cause systemic involvement, disability, and other serious complications. 2 The lack of strong evidence of DMARDs efficacy and safety in children renders difficult the decision to include these agents in the WHO Model List. 3 DMARDs are used as second or third line therapy in those conditions. Patients are commonly responders to corticosteroids and supportive care. Despite these aspects, in the event that the Committee should decide for the inclusion of DMARDs, my suggestions are:
3 1. Not to include mycophenolate mofetil that showed no different responses over intravenous cyclophosphamide as induction treatment for lupus nephritis in adults. 1 Both treatments showed remission in the renal system, as well as in other systems. There was no clear difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide in ameliorating either the renal or nonrenal manifestations in adults. 2 In four children with severe lupus nephritis, who previously received short term, low dose intravenous cyclophosphamide plus mizoribine and corticosteroids as induction therapy, mycophenolate permitted a significant reduction in mean prednisolone dose (P = 0.003) in the maintenance therapy. No renal flares were observed, neither significant gastrointestinal or hematologic side effects. This promising intervention should be confirmed by a prospective randomised multicenter clinical trial. 3 In long term monotherapy, mycophenolate appears to have a greater risk in pregnancy and increased reports of herpes simplex and zoster infection compared to cyclosporinee. 4 I did not find reference to mycophenolate efficacy in other phases of SLE or in the other rheumatic diseases here considered. 1. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77(2): Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomised, open label, parallel group clinical trial. Arthritis Rheum 2010; 62(1): Fujinaga S, Ohtomo Y, Hara S, Umino D, Someya T, Shimizu T, Kaneko K. Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low dose intravenous cyclophosphamide regimen. Pediatr Nephrol 2008; 23(10): Buell C, Koo J. Long term safety of mycophenolate mofetil and cyclosporinee: a review. J Drugs Dermatol 2008; 7(8): Not to include leflunomide because methotrexate and leflunomide both resulted in high rates of clinical improvement of patients with polyarticular juvenile rheumatoid arthritis, but the rate was slightly greater for methotrexate. At the doses used in this study (a multinational, randomised, controlled trial, n=86, 3 17 years old), methotrexate was more effective than leflunomide. 1 Despite the suggestion of benefit with the use of leflunomide in the paediatric population, the exact role is yet to be defined. 1. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al.; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352 (16): Not to include sulfasalazine (SSZ) despite the clinical benefit observed in few controlled studies performed in adults. According to the previous review, sulfasalazine does not have consistent efficacy across subtypes of JIA. On the current evidence, sulfasalazine is not effective in the management of JIA and, in fact, its use is potentially complicated by an increased and frequent risk of toxicity. A trial randomised patients with oligo and polyarticular onset juvenile idiopathic arthritis to receive sulfasalazine (n=32) or placebo (n=29) during 24 weeks. An extension of this study evaluates whether the benefits showed with SSZ are sustained over time (median 9 years). At the final of the follow up, 74% of the patients had active joints, and 30% showed active polyarthritis. Almost all outcome scores were better for SSZ compared with placebo. 1 For juvenile onset SLE, there are few randomised controlled studies with a small number of patients.
4 A randomised, double blind, placebo controlled exploratory study (n=33) demonstrated no significant difference in response rate (number of active joints as a primary outcome) in patients with juvenile onset spondyloarthropathies. Differences between groups were only significant in the doctor and patient assessments of improvement and the number of changes of concomitant treatment (2 vs. 8; P=0.026) van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, et al.; Dutch Juvenile Idiopathic Arthritis Study group. Long term outcome of juvenile idiopathic arthritis following a placebo controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007; 66 (11): Burgos Vargas R, Vázquez Mellado J, Pacheco Tena C, Hernández Garduño A, Goycochea Robles M V. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002; 61: Not to include cyclosporine A for JIA and JDM treatment. The role of cyclosporine in the treatment of JIA has not been clearly defined. There is little strong evidence supporting its efficacy, and there are no controlled trials. Evidence includes observational studies and case series. There are few and small retrospective studies and case series reporting the benefits of cyclosporine in patients with JDM. Cyclosporine is associated with potentially considerable toxicity and requires careful monitoring and supervision. Adverse events and lack of efficacy or flare of disease cause a high percentage of withdrawal. Most side effects are dose dependent and responsive to dose adjustment. 5. Not to include azathioprine (AZA) due to the current lack of strong evidence of efficacy for the management of rheumatic diseases in children. The evidence for the efficacy of azathioprine is based on case series, case reports and uncontrolled trials. Concerning safety, AZA is associated with higher risk of serious side effects. Besides, for those diseases there are different options more reliable and with a better toxicity profile. AZA has been used for the management of Systemic Lupus Erythematosus (SLE) in children for decades. Despite this long experience, there are no controlled trials addressing its efficacy in paediatric lupus and therefore its use remains controversial. Azathioprine is used in a variety of clinical circumstances in SLE but most frequently in combination with corticosteroids. The addition of azathioprine as second line therapy may be indicated to permit steroid dose reduction in patients requiring unacceptably high doses of corticosteroids. The role of azathioprine in the management of paediatric lupus complicated by nephritis is even less well defined. On the other hand, a study of lupus nephritis in children concluded that long term outcome was excellent with 94% survival at mean follow up of 11 years. In this group of patients, azathioprine was the most frequently prescribed agent. 1 AZA is not used routinely in the treatment of JIA. Azathioprine is associated with potentially serious side effects in particular relating to bone marrow suppression. Sulfasalazine and azathioprine are among the most important causes of acute hepatotoxicity. 2 In a cohort study, a significant proportion of rheumatologic patients on AZA had drug related toxicity resulting in discontinuation of AZA Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, et al. Longterm follow up of childhood lupus nephritis. J Rheumatol 2002; 29(12): Aithal GP; Medscape. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011 Jan 25. [Epub ahead of print] 3. Jabin D, Kumar S, Gow PJ. Outcome of patients on azathioprine: a need for a better pre treatment assessment and dosing guideline. N Z Med J 2010; 123 (1324):
5 6. To include hydroxychloroquine (HCQ) due to its broad spectrum of beneficial effects and safety profile, despite the main studies supporting its use in SLE were performed in adults. Additional effects beyond immunomodulation have been recently described. A systematic review 1 of a total of 95 articles demonstrated high levels of evidence that HCQ prevents SLE flares and increases long term survival of patients with SLE. There was moderate evidence of protection against irreversible organ damage, thrombosis and bone mass loss. Toxicity related to antimalarials is infrequent, mild and usually reversible, with HCQ having a safer profile. Recommendations are that HCQ should be given to most patients with SLE during the whole course of the disease, irrespective of its severity. HCQ is approved for the treatment of SLE and has been shown to reduce the frequency of disease flares (particularly of lupus nephritis), contribute to the maintenance of remission, prolong the onset of disease and reduce the risk of complications. 2 Its low cost contributes to a systematic prescription in SLE patients. Hydroxychloroquine is frequently used as an adjunct to steroid therapy at the onset of treatment of juvenile SLE. However, there are no trials addressing the effectiveness of hydroxychloroquine in the paediatric population. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) recommends hydroxychloroquine for milder cases of juvenile dermatomyositis and cases mainly characterized by rash. 3 Antimalarials have been used for the treatment of rheumatoid arthritis (RA) for several decades. Recently several trials have been published with larger sample sizes, and better design than previous studies. Hydroxychloroquine is generally considered to be a very safe medication, and it does need regular monitoring. Full blood examination is suggested on a regular basis and ophthalmology examination should occur at least yearly. 1. Ruiz Irastorza G, Ramos Casals M, Brito Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69(1): Dörner T. Therapy: Hydroxychloroquine in SLE: old drug, new perspectives. Nature Reviews Rheumatology 2010; 6: Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol 2010; 37(9): To include methotrexate (MTX), often considered as the first choice in the treatment of rheumatic diseases such as: JIA, JDM, SLE, vasculitis, uveitis and localized scleroderma. Additionally, short and long term data suggest that MTX is a safer drug in the paediatric population with rheumatic diseases. 1 In JIA, methotrexate is the most frequently used second line agent and there is good evidence of its efficacy. MTX is considered the standard treatment of JIA, particularly of those subgroups with polyarticular course. JIA response and remission rates to MTX are the standard for comparison with other drug modifying anti rheumatic drug (DMARD) and biologic agents in clinical trials. Not surprisingly, MTX is the DMARD of choice in JIA either as monotherapy drug or in combination with biologic agents. 1 To examine the change in health related quality of life (HRQOL) and its determinants in children with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX) 521 children were extracted from the PRINTO clinical trial. At baseline, patients with JIA showed poorer HRQOL than healthy children (P<0.01). After 6 months of treatment with standard dose MTX, there was a statistically significant improvement in all HRQOL health concepts, particularly in the physical domains. Similar improvements were observed in those who did not respond to a standard dose of MTX and were subsequently randomised
6 to a higher dose. 2 However, a Cochrane systematic review of only two studies (n=165 JIA patients under 18 years of age) showed small to moderate effects on patients centered disability outcomes with a relative percentage improvement from 3 to 23% greater with MTX than with placebo. 3 In patients with polyarticular course juvenile idiopathic arthritis the poorer response to a 6 month MTX course was significantly associated with longer disease duration, anti nuclear antibody negativity, higher disability and presence of wrist activity. 4 In this condition, patients (n=133) who do not improve with MTX standard doses (8 10 mg/m 2 /week) were randomised to receive parenteral MTX at an intermediate dosage (15 mg/m 2 /week) versus a higher dosage (30 mg/m 2 /week) for 6 months. This study showed that the plateau of efficacy of MTX in JIA is reached with parenteral administration of 15 mg/m 2 /week and that a further increase in dosage is not associated with any additional therapeutic benefit. MTX should be administered for up to 9 12 months to appreciate its full therapeutic effect. There were no significant differences in the frequency of adverse events or laboratory abnormalities between the two randomised groups. 5 In patients with JIA in remission, a 12 month vs. 6 month withdrawal of methotrexate did not reduce the relapse rate. 6 The use of methotrexate is safe in combination with NSAIDS and corticosteroids. This medicine is well tolerated by children and adolescents. Side effects occur mainly in the form of gastro intestinal discomfort such as nausea and vomiting or raised transaminases, which can be effectively treated with folic acid supplementation. 7 Most of the other side effects are mild and reversible. Children are thought to have a reduced risk of methotrexate associated hepatotoxicity compared with adults. These changes are usually transient and improve with a period of cessation. Haematological abnormalities are rare with the use of methotrexate. Malignancy due to methotrexate remains an area of controversy. In JDM, methotrexate is the most frequently used of the immunosuppressive agents. A survey 8 conducted among 167 American pediatric rheumatologists showed that 84% (141) prescribed corticosteroids and another medication, methotrexate being the most commonly used, for typical cases of JDM, regardless of severity. In a Brazilian registry of juvenile dermatomyositis (189 cases included), prednisone methotrexate combination was the most indicated treatment. 9 Methotrexate has not been subjected to a prospective randomised controlled trial and therefore evidence for its use is derived from observational studies only. There is currently an international multi centre prospectively randomised trial co ordinated by PRINTO (Paediatric Rheumatology International Trials Organisation) which is comparing prednisolone alone with prednisolone/methotrexate combination and prednisolone/ cyclosporinee combination in patients newly diagnosed with JDM. The results of this trial are eagerly awaited in order to guide the management of JDM. MTX use requires monitoring with blood tests and close clinical supervision from a medical specialist familiar with the potential risks. It is not recommended for use if access to this supervision is unavailable. It is recommended for inclusion on the WHO complementary list of essential medicines. 1. Gutiérrez Suárez R, Burgos Vargas R. The use of methotrexate in children with rheumatic diseases. Clin Exp Rheumatol 2010; 28 (5 Suppl 61): S Céspedes Cruz A, Gutiérrez Suárez R, Pistorio A, Ravelli A, Loy A, Murray KJ, et al; Pediatric Rheumatology International Trials Organization (PRINTO). Methotrexate improves the health related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 2008; 67(3): Takken T, van der Net JJ, Helders PPJM. Methotrexate for treating juvenile idiopathic arthritis. Cochrane
7 Database of Systematic Reviews. In: The Cochrane Library, Issue 12, Art. No. CD Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, et al.; Pediatric Rheumatology International Trials Organisation (PRINTO). Predictors of poor response to methotrexate in polyarticular course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis 2010; 69 (8): Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al.; Pediatric Rheumatology International Trials Organization. A randomised trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50(7): Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al.; Paediatric Rheumatology International Trials Organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303 (13): Holzinger D, Frosch M, Föll D. Methotrexate in the therapy of juvenile idiopathic arthritis. Z Rheumatol 2010; 69(6): Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol 2010; 37 (9): Sato JO, Sallum AM, Ferriani VP, Marini R, Sacchetti SB, Okuda EM, et al; Rheumatology Committee of the São Paulo Paediatrics Society. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 2009; 27(6):
The Use of Methotrexate in Juvenile Idiopathic Arthritis: A Single Center Experience
HK J Paediatr (new series) 2006;11:191-198 The Use of Methotrexate in Juvenile Idiopathic Arthritis: A Single Center Experience PPW LEE, TL LEE, WHS WONG, YL LAU Abstract Key words In the recent decade,
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationLONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS. Hong Kan 7/12/2016
LONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS Hong Kan 7/12/2016 1 Acknowledgements Research conceptualization and design, programming
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationBIOLOGIC THERAPY : A NEW OPTION FOR TREATMENT JUVENILE IDIOPATHIC ARTHRITIS DR TON THAT HOANG
BIOLOGIC THERAPY : A NEW OPTION FOR TREATMENT JUVENILE IDIOPATHIC ARTHRITIS DR TON THAT HOANG INTRODUCTION JIA is the most common chronic rheumatic inflammatory disease of childhood. If not successfully
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationUpdate on Enthesitis-Related Arthritis, a Subtype of Juvenile Idiopathic Arthritis
Hong Kong Bull Rheum Dis 2010;10:15-19 Review Article Update on Enthesitis-Related Arthritis, a Subtype of Juvenile Idiopathic Arthritis Tsz-Leung Lee Abstract: Keywords: Enthesitis related arthritis (ERA)
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationArthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS
Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Introduction: There is perhaps no rheumatic disease that evokes so much fear and confusion among both patients
More informationRheumatoid arthritis in adults: diagnosis and management
National Institute for Health and Care Excellence Consultation Rheumatoid arthritis in adults: diagnosis and management Evidence review F DMARDs NICE guideline CG79 Intervention evidence review January
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationJuvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children
Tiller et al. Pediatric Rheumatology (2018) 16:69 https://doi.org/10.1186/s12969-018-0288-z RESEARCH ARTICLE Open Access Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of
More informationClinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December Reference : NHSCB/A3C/1b
Clinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December 2012 Reference : NHSCB/A3C/1b NHS Commissioning Board Clinical Commissioning Policy Statement: Rituximab
More informationRecommendations for RA management: what has changed?
The 2016 Update of the EULAR Recommendations for RA management: what has changed? Baltics Rheumatology Conference Vilnius, September 21-22 Prof. Diego Kyburz University Hospital of Basel Switzerland Multiple
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationSYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS. Dr Sheila Vasoo Consultant Division of Rheumatology NUHS
SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS Dr Sheila Vasoo Consultant Division of Rheumatology NUHS Listen to the Patient Concepts Diagnosis Immunopathogenesis Clinical Pearls Disease
More informationMethotrexate Injectable Step Therapy Program Summary
Methotrexate Injectable Step Therapy Program Summary This prior authorization applies to Commercial, SourceRx and Health Insurance Marketplace formularies. OBJECTIVE The intent of the methotrexate injectable
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More informationOpinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 IMUREL 50 mg, film-coated tablet (B/100) (CIP: 34009 364 149 0 7) IMUREL 25 mg, film-coated tablet (B/50)
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationDEPARTMENT OF RHEUMATOLOGY
DEPARTMENT OF RHEUMATOLOGY PG Teaching Schedule Theory (8 30 am to 9am) DATE TOPIC PRESENTER FACULTY 01/10/16 Approach to Arthritis Dr. Sandeep Dr. Suma Balan 03/10/16 Cardiovascular risk in Rheumatic
More information2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH LOUISIAA (MEDICAID) Remicade (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More information3. Does the patient have a diagnosis of rheumatoid arthritis (RA) with moderate to high disease activity?
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Enbrel (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More information3. Has the patient shown improvement in signs and symptoms of the disease? Y N
Pharmacy Prior Authorization MERC CARE (MEDICAID) Orencia (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed
More informationOverview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationTitle: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs.
Title: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs. Background Juvenile idiopathic arthritis (JIA) is not
More information2. Does the patient have a diagnosis of giant cell arteritis (GCA)? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Actemra (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More information3. Is the prescribed dose within the Food and Drug Administration (FDA)- approved dosing for giant cell arteritis?
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Actemra (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationDisclosures. Evidence Based Medicine. Infections in SLE and LN Patients. Aim
Serious Infection Rates among Patients with Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants None Disclosures Candace H. Feldman, MD, MPH 1,2 Linda T. Hiraki, MD, SM, ScD 3
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationSwitching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes
Arthritis Care & Research Vol. 66, No. 12, December 2014, pp 1905 1909 DOI 10.1002/acr.22364 2014, American College of Rheumatology ORIGINAL ARTICLE Switching Treatment Between Mycophenolate Mofetil and
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationClinical Commissioning Policy Proposition:
Clinical Commissioning Policy Proposition: Rituximab for the treatment of dermatomyositis and polymyositis (Adults) Reference: NHS England A13X05/01 Information Reader Box (IRB) to be inserted on inside
More informationCircle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Humira (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationLupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?
Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Enbrel (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationDRUG THERAPY
www.pediatric-rheumathology.printo.it DRUG THERAPY NSAIDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS They are symptomatic anti-inflammatory, anti febrile (fever) and analgesic (pain reducing) medications. Symptomatic
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationRegulatory Status FDA-approved indication: Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: Oct 1, 2016 Subject: Enbrel Page: 1 of 7 Last Review Date:
More information29/10. Treatment (brand name, manufacturer): For the treatment of: Background: Rituximab (MabThera, Roche) SLE in adults (unlicensed)
GENERAL POLICY Policy Ref: 29/10 Treatment (brand name, manufacturer): For the treatment of: Background: Commissioning position: Rituximab (MabThera, Roche) SLE in adults (unlicensed) There are frequent
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationTRANSPARENCY COMMITTEE. Opinion. 29 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 November 2006 HEXATRIONE 2% suspension for injection (intra-articular) Box containing one 2-ml vial - CIP code:
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationLupus nephritis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
Lupus nephritis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas, Chemocentryx,
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: belimumab_benlysta 6/2011 2/2018 2/2019 3/2018 Description of Procedure or Service Belimumab (Benlysta) is
More informationPrior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax
Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Humira (adalimumab) require a prior
More informationSystemic Lupus Erythematosus
A Patient s Guide to Systemic Lupus Erythematosus 2 kidneys. These changes make it impossible for the kidneys to function normally. The inflammation of SLE can be seen in the lining, covering, and muscles
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationNon-commercial use only
Reumatismo, 2016; 68 (2): 90-96 Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study K.T. Koh 1, C.L. Teh 2,
More informationTHERAPY in RHEUMATOLOGY
THERAPY in RHEUMATOLOGY RA OA AS Systemic diseases SLE Dermatomyositis Scleroderma Gout Rheumatic fever Lyme disease RHEUMATOID ARTRHRITIS Education Build a cooperative long-term relationship Use materials
More information(minutes for web publishing)
Rheumatology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 17 October 2017 (minutes for web publishing) Rheumatology Subcommittee minutes are published in
More informationACTEMRA (tocilizumab)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More information2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N
12/21/2016 Prior Authorization Aetna Better Health of West Virginia Humira (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Examination of the dossier of medicinal products included on the reimbursement list for a period of 5
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. José María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. José María Pego Reigosa ABSTRACT NUMBER: 2754 Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions:
More informationIdentification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
To cite: Dall Era M, Levesque V, Solomons N, et al. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Science
More informationFigure 1. Study flow diagram. Reasons for withdrawal during the extension phase are included in the flow diagram. 508 patients enrolled and randomized
508 patients enrolled and randomized 126 assigned to sequential monotherapy (group 1) 121 assigned to step-up combination therapy (group 2) 133 assigned to initial combination therapy with prednisone (group
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationEfficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study.
1. Title Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 2. Background Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and
More informationKDIGO GN Guideline update Evidence summary. Steroid-sensitive nephrotic syndrome. Corticosteroid therapy for nephrotic syndrome in children
KDIGO GN Guideline update Evidence summary Steroid-sensitive nephrotic syndrome Corticosteroid therapy for nephrotic syndrome in children PICO question In children (aged 3 to 18 years of age) with steroid-sensitive
More informationThe use of methotrexate in rheumatological conditions A review of the evidence. Maureen Cox January 2009
The use of methotrexate in rheumatological conditions A review of the evidence Maureen Cox January 2009 Visser et al Multinational evidence based recommendations for the use of methotrexate in rheumatic
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationPaediatric rheumatology. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases
Paediatric rheumatology A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases J.O. Sato 1 *, A.M.E. Sallum 2 *, V.P.L. Ferriani 3, R. Marini 4, S.B. Sacchetti
More informationPrior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD
Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):
More informationPHARMACY POLICY STATEMENT Ohio Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Ohio Medicaid Enbrel (etanercept) Must use
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),
More informationERROR CORRECTION FORM
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Registry Use Only Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic, syngeneic unrelated related
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed:
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic,
More informationAd-Hoc Rheumatology Subcommittee of PTAC meeting held 8 March. (minutes for web publishing)
Ad-Hoc Rheumatology Subcommittee of PTAC meeting held 8 March 2011 (minutes for web publishing) Ad-Hoc Rheumatology Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationPediatric rheumatic diseases (PRDs) are rare
World Journal of Pediatrics Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization Nicolino Ruperto, Alberto Martini Genova, Italy 186 Background:
More informationDeciding what to do about Rheumatoid Arthritis
Shared Decision Making rheumatoid arthritis Next clinical review date March 2018 Deciding what to do about Rheumatoid Arthritis This short decision aid is to help you decide what treatment to have if you
More informationTHE MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS
THE MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS Prof Chris Scott PAEDIATRIC RHEUMATOLOGIST UNIVERSITY OF CAPE TOWN RED CROSS WAR MEMORIAL CHILDRENS S HOSPITAL Chronic Arthritis >6wks JIA No other cause
More informationOutcome in Juvenile Rheumatoid Arthritis in India
Outcome in Juvenile Rheumatoid Arthritis in India Amita Aggarwal, Vikas Agarwal, Debasish Danda and Ramnath Misra From the Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences,
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationEffect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus.
Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine 10-22-2015 Effect of mycophenolate mofetil on the white blood cell count and the frequency
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationAppendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag
More informationTransla&onal Opportuni&es
Suppor&ng the UK s Transla&onal Research in Paediatric Rheumatology Experience of the UK s Paediatric Rheumatology Clinical Studies Group West Midlands Annual Mee.ng Birmingham, 4 th July 03 Professor
More informationKelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition
Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition Firestein, G ISBN-13: 9781437717389 Table of Contents VOLUME I STRUCTURE AND FUNCTION OF BONE,
More information